Meeting
2018 Gastrointestinal Cancers Symposium
Prediction of overall survival for metastatic pancreatic cancer treated with gemcitabine monotherapy: Development and external validation of a prognostic nomogram with open clinical trial data.
Authors
Junjie Hang
The Changzhou Second People’s Hospital Affiliated With Nanjing Medical University, Changzhou, China
Junjie Hang , Lixia Wu , Jiadi Du , Hua Jiang , Kequn Xu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Prevention, Diagnosis, and Screening
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 237)
DOI
10.1200/JCO.2018.36.4_suppl.237
Abstract #
237
Poster Bd #
B12
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Real-world patterns of care among patients with metastatic pancreatic cancer (mPC).
First Author: Eileen Mary O'Reilly
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Ciprofloxacin plus gemcitabine-based chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma: A pilot study of microbiome manipulation.
First Author: Seng Wee Cheo
Poster
2019 Gastrointestinal Cancers Symposium
Dose intensity of nab-paclitaxel and gemcitabine chemotherapy in metastatic pancreatic cancer.
First Author: Alexander Lim
Poster
2018 Gastrointestinal Cancers Symposium
Folfirinox (FFX) versus gemcitabine with nab‐paclitaxel (GNP) in the first line treatment (1LTx) of metastatic pancreatic cancer (mPC): A tertiary center experience.
First Author: Ivan Barrera